# Feasibility for Development of a Liposome/LNP Displaying an HIV Env Trimer Protein and Containing/Incorporating an mRNA

> **NIH NIH N01** · DUKE UNIVERSITY · 2024 · $2,456,817

## Abstract

Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS): This program will provide NIAID with a broad and flexible range of capabilities that are required for preclinical and translational development support for promising vaccines and related products for HIV and other candidate agents. Contracts under this program will provide the support and services needed for all stages of process and product development, small-scale production, preclinical testing and documentation leading to Investigational New Drug (IND) submissions for Phase I, II, and III clinical testing. These capabilities will allow NIAID to rapidly and efficiently address development and production gaps. This contract will provide support under Task Area C: Feasibility Studies and Early Manufacturability Assessments.

## Key facts

- **NIH application ID:** 11181783
- **Project number:** 75N93022D00003-0-759302400001-1
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** —
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,456,817
- **Award type:** —
- **Project period:** 2024-08-31 → 2028-08-27

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11181783

## Citation

> US National Institutes of Health, RePORTER application 11181783, Feasibility for Development of a Liposome/LNP Displaying an HIV Env Trimer Protein and Containing/Incorporating an mRNA (75N93022D00003-0-759302400001-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11181783. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*